Argenx Rises as FDA Clears Vyvgart Hytrulo Injection: Streetwrap

(Updates to add share move and analyst comments)

Argenx rises as much as 3.3% after the US drug regulator approved Vyvgart Hytrulo subcutaneous injection to treat generalized myasthenia gravis. KBC says the subcutaneous option now provides for a more patient-friendly solution even though it will be administered by a healthcare professional.

• NOTE: Generalized myasthenia gravis is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness
  • Efficacy of Vyvgart Hytrulo was established by demonstrating a comparable pharmacodynamic effect to Vyvgart in Phase 3 ADAPT-SC bridging study, according to ...